Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21012851 | 0.85 | ALDH1A1 (0.33) | HTR1ADRD4HTR2ASLC6A4HTR7 | |
| SCHEMBL3581854 | 0.82 | PDE10A (0.44) | HTR1ADRD4HTR2ASLC6A4HTR7 | |
| SCHEMBL3576177 | 0.82 | DRD4 (0.50) | HTR1ADRD4HTR2ASLC6A4HTR7 | |
| SCHEMBL22837868 | 0.80 | SORD (0.35) | MAPTHDAC1HRH4 | |
| SCHEMBL4522600 | 0.77 | HDAC1 (0.47) | DRD4MAPTHRH3NMT1HDAC1 | |
| SCHEMBL22569545 | 0.75 | DRD4 (0.55) | HTR1ADRD4HTR2ASLC6A4HTR7 | |
| SCHEMBL3393966 | 0.75 | ACACB (0.44) | HTR1ADRD4HTR2ASLC6A4HTR7 | |
| SCHEMBL4517650 | 0.75 | HDAC1 (0.46) | DRD4HRH3NMT1HDAC1HRH4 | |
| SCHEMBL1450231 | 0.74 | OGA (0.37) | HRH3 | |
| SCHEMBL13187431 | 0.74 | KCNH2 (0.36) | MAPTHDAC1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | claimed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | claimed |
| EP-1987031-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NeuroSearch A/S (DK) | 2008-11-05 | — | — | EP | claimed |
| WO-2007090888-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | claimed |
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | disclosed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | CHRNA3, CHRNA10, CHRNB3 | HTR1A 80/4885DRD4 264/4885HTR2A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.